his.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Specific Copy Number Alterations Associated with Docetaxel/Carboplatin Response in Ovarian Carcinomas
University of Gothenburg.
University of Gothenburg.
University of Gothenburg.
University of Gothenburg.
Visa övriga samt affilieringar
2010 (Engelska)Ingår i: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 30, nr 11, s. 4451-4458Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: The continued high recurrence and mortality rate in ovarian cancer is a significant problem and the major obstacle in the treatment of ovarian cancer patients is chemotherapy resistance. Thus, finding predictive markers of chemoresistance and elucidating resistance mechanisms is crucial for individualising treatment and improving survival of ovarian cancer patients. Materials and Methods: Using array comparative genomic hybridisation (CGH), this pilot study analysed the tumour genomes of patients treated with docetaxel/carboplatin as first-line chemotherapy (6 resistant versus 24 sensitive cases). This is the first array CGH study of  such  material.  Results:  The  study  identified  genetic alterations specific to chemoresistant (gains in 9p13.2-13.1, 9q21.2-21.32,  9q21.33,  9q22.2-22.31,  9q22.32-22.33  and 9q33.1-34.11) and chemosensitive (losses in 8p23.3-23.1 and 8p22) disease. Additionally, when comparing the results to previously analysed tumour material from patients treated with paclitaxel/carboplatin, the two datasets identified different genetic  alteration  profiles.  Conclusion:  Specific  genetic alterations were identified and associated with chemotherapy response in ovarian cancer. It will be interesting to investigate these exciting data further in larger independent series of ovarian   tumours,   and   hopefully   will   contribute   to   the establishment of predictive markers.

Ort, förlag, år, upplaga, sidor
Highwire Press , 2010. Vol. 30, nr 11, s. 4451-4458
Nyckelord [en]
Ovarian cancer, docetaxel, carboplatin, chemotherapy resistance, array CGH
Nationell ämneskategori
Naturvetenskap
Forskningsämne
Naturvetenskap
Identifikatorer
URN: urn:nbn:se:his:diva-4681ISI: 000285237100009PubMedID: 21115892Scopus ID: 2-s2.0-78650240757OAI: oai:DiVA.org:his-4681DiVA, id: diva2:393509
Tillgänglig från: 2011-01-31 Skapad: 2011-01-31 Senast uppdaterad: 2017-12-11Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

PubMedScopus

Personposter BETA

Olsson, Björn

Sök vidare i DiVA

Av författaren/redaktören
Olsson, Björn
Av organisationen
Forskningscentrum för SystembiologiInstitutionen för vård och natur
I samma tidskrift
Anticancer Research
Naturvetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetricpoäng

pubmed
urn-nbn
Totalt: 988 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf